|
||||||||||
|
||||||||||
|
ABCD nationwide and worldwide dapagliflozin audit
Webcasts Webcast of ABCD research fellow Dr Mahender Yadagiri presenting ABCD dapagliflozin audit poster at EASD, Munich, 13 September 2016
Ken Yan Thong, Mahender Yadagiri, Dennis Joseph Barnes, David Stuart Morris, Tahseen Ahmad Chowdhury, Ling Ling Chuah, Anthony Michael Robinson, Stephen Charles Bain, Karen Ann Adamson, Robert Elford John Ryder, ABCD Nationwide Dapagliflozin Audit contributors: Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit
Primary Care Diabetes pcd.2017.06.004
Slides from presentations
ABCD Autumn meeting, London, November 6 2015
Abstracts DUK, Glasgow, 2016a: – M Yadagiri, P Sen Gupta, ML Cull, J Eyles, A Robinson, L Oguntolu, K Imtiaz, K Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin Audit Contributors. HbA1c,weight,body mass index(BMI) and systolic blood pressure changes in the ABCD nationwide audit(poster presentation:P432). Diabetes 2016 Jul; 65 (Supplement 1): 1164-P DUK, Glasgow, 2016b: – M Yadagiri, P Sen Gupta, JW Stephens, A Robinson, M Phylactou, A Kennedy, J Clark, J Wilding, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin Audit Contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase and Type 2 diabetes? The Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit(oral presentation:A73/P427). Diabetic Medicine 2016. 33 (Suppl 1): Abstract A73. ABCD Spring Meeting 2016, Manchester - K.Y. Thong, M. Yadagiri, P. Sen Gupta, P. Winocour, M. Joshi, J. Wilding, JW Stephens, SC Bain, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. The glycaemic response to dapagliflozin according to intensity of background diabetes treatment or duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation : Abstract 3. Diabetes 2016 Jul; 65 (Supplement 1): 1170-P ADA New Orleans, 2016a - M. Yadagiri, P. Sen Gupta, ML Cull, D. Price, V Oguntolu, K Imtiaz, D Barnes, A Nugent, A Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes? The Association of British Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1123-P ADA New Orleans, 2016b – M. Yadagiri, P. Sen Gupta, A. Kennedy, T. Pang, J. Clark, H. Pathan, P.C. Johnston, R. Chudleigh, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. HbA1c,weight, body mass index(BMI) and systolic blood pressure response to dapagliflozin: The Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1164-P ADA New Orleans, 2016c - K.Y. Thong, M. Yadagiri, P. Sen Gupta, P. Winocour, M. Joshi, J. Wilding, JW Stephens, SC Bain, A. Robinson, IW Gallen, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. The glycaemic response to dapagliflozin according to intensity of background diabetes treatment or duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1170-P EASD Munich, 2016 - M Yadagiri, P Sen Gupta, T Pang, L Balmuri, T Robinson, S Bain, IW Gallen, KA Adamson, REJ Ryder on behalf of ABCD nationwide dapagliflozin audit contributors. Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications: Association of British Clinical Diabetologists(ABCD) nationwide dapagliflozin audit –Diabetologia(2016) Vol 59 Supplement 1: S581- Abstract 712. DUK Manchester, 2017 - M Yadagiri, P Sen Gupta, A Kennedy, T Pang, L Balmuri, T Robinson, S Bain, IW Gallen, KA Adamson, REJ Ryder on behalf of ABCD nationwide dapagliflozin audit contributors. The effect of dapagliflozin on HbA1c and weight after its addition to commonly prescribed dual combination diabetes medication regimes in people with Type 2 diabetes in a real-world UK setting: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit – Diabetic Medicine volume 34 (Supplement S1, 36-194) - Poster 519 ADA San Diago, 2017a - M Yadagiri, S C Bain, T Robinson, JPH Wilding, T Pang, B McGowan, P Winocour, V Oguntolu, J Clark, H Partridge, IW Gallen, KA Adamson, REJ Ryder, ABCD nationwide dapagliflozin audit contributors. Dapagliflozin in Renal Impairment : the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit – Diabetes June 2017 Volume 66 (Supplement 1, A45) : Oral 172-OR ADA San Diego,2017b - KY Thong, M Yadagiri, P Tong, D Barnes, D Morris, T Chowdhury, LL Chuah, M Cohen, A Kennedy, T Robinson, SC Bain, KA Adamson, REJ Ryder and the ABCD Nationwide Dapagliflozin audit contributors. Lack of risk factors predicting the development of genital mycotic infections among patients treated with dapagliflozin : the Association of British Clinical Diabetologists Nationwide Dapagliflozin audit. Poster presentation: 1287-P
Posters DUK Professional Conference, Glasgow, March 4 2016a DUK Professional Conference, Glasgow, March 4 2016b
ABCD
Manchester, Spring 2016 DUK Professional Conference, Manchester, March 2017
|
ABCD dapaglflozin audit homepage Register for the dapagliflozin audit Register simulateously for both dapagliflozin and exenatide qw audits
Access
the on-line tool
Access the worldwide on-line tool Dapagliflozin audit objectives Order preprinted data entry forms Download first visit data entry form Download follow up visit data entry form Papers, abstracts, presentations, posters from the audit |
||||||||
|
The ABCD nationwide dapagliflozin audit is an independent audit supported by an unrestricted grant from Astra Zeneca |
||||||||||
|
Working to support high quality diabetes care in the UK |
||||||||||
|
|
||||||||||
